10707 results for 'make bind left'

Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi

Protocols & Assay Guides | ELISA, Multiplex, Western Blot | Assay Genie

What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What

Inflammasomes are complex intracellular structures that play a pivotal role in the immune response by detecting pathogenic microorganisms and sterile stressors. Their activation is a critical step

Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα

Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic res

Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec

Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase

Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator

Immunohistochemistry (IHC) stands as a critical tool in the realm of biomedical research and diagnostic practices, offering a bridge between molecular insights and the intricate visualization of t

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b

The germinal centre is where antibody quality is made. A naive B cell that binds antigen does not become a source of protective, high-affinity IgG by accident. It passes through a tightly choreograph

TUNEL Assay Kits | 1-Step In Situ Apoptosis Detection | Assay Genie

You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a

PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap

Western Blot Protocol & Troubleshooting Guide | 14 Steps + 101 Tips | Assay Genie

Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression

QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part

T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is an immune checkpoint receptor that plays a pivotal role in T cell exhaustion, a state where T cells lose their ability to ef

Every T-cell response begins with a protein being taken apart. Before a CD8 or CD4 T cell can see anything, an antigen has to be degraded into peptides of the right length, delivered to the right com

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune

Quick Facts About CarlumabWhat is Carlumab?Carlumab is a monoclonal antibody developed to target CC-chemokine ligand 2 (CCL2), a key mediator in inflammatory diseases and cancer progress

Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus A groundbreaking study published in November 2025 has provided the most definitive evidence to date that the common E

Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth

The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C

Immunology · NeuroscienceHistamine Receptors: H1, H2, H3 & H4 ExplainedHistamine receptors are the G protein-coupled receptors through which histamine controls allergy, gastric acid secretion, neurotr

What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen

For decades, the fight against cancer has been a grueling battle of attrition, with treatments often as harsh as the disease itself. But a revolutionary approach, chimeric antigen receptor (CAR)-T cel

Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signa

Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab

Introduction to FoxP3 and Regulatory T Cells in CancerFoxP3 (forkhead box P3) is a transcription factor critical for the development and function of regulatory T cells (Tregs), a speciali

QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most

A chimeric antigen receptor is a synthetic protein wired into a real signalling pathway. The extracellular half is an antibody fragment; everything below the membrane is borrowed from the T-cell rece

In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu

Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate

IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr

Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa

Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio

Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T

Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe

Quick answer A researcher validating two isoform assays — the Human ALT1 (HUFI00557) and ALT2 (HUFI00593) ELISA kits — spiked the ALT2 kit's standard onto the ALT1 kit's plate and saw

What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is

Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does

Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc

Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous

L’effet crochet est une chute paradoxale du signal ELISA lorsque la concentration d’analyte devient trop élevée, ce qui produit un résultat faussement bas, voire négatif. Il touche surtout les for

Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor